Insights

Wegovy

Earnest Analytics
  • Consumer
  • Retail

GLP-1s powering Hims & Hers Health, Ro sales growth in 2024
  • Healthcare
  • Pharmacy

GLP-1 Series Part 4: End of Mounjaro’s bridge program drove improved gross-to-net
  • Healthcare
  • Pharmacy

GLP-1 Series Part 3: Mounjaro driving largest declines in insulin usage
  • Healthcare
  • Pharmacy

GLP-1 Series Part 2: Mounjaro persistence beats Ozempic in type II diabetes
  • Healthcare
  • Pharmacy

GLP-1 Series Part 1: Utilization drives decline in DPP-4 inhibitors, increase in SGLT2s among competitive drug classes
  • Healthcare
  • Pharmacy

Wegovy is Back on Shelves, Picking up Ozempic’s Momentum in Obesity
arrow-downarrow-leftarrow-rightcaret-down-menucaret-downcarrot-rightcheckclosefacebook-squarefilterhamburgerinstagram-squarelinkedin-squaremobile-parent-indicatorpauseplayprintertwitter-square